ArticleEuropean journal of clinical pharmacology2019
Tamoxifen administration and the risk of Parkinsonism.
François Montastruc, Farzin Khosrow-Khavar, Agnès Sommet, Christel Renoux, Jean-Louis Montastruc
Abstract readLetterComment
In one paragraphArticle in European journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
5 authors.
François MontastrucService de Pharmacologie Médicale et Clinique, Centre de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CIC INSERM 1436, NeuroToul Centre of Excellence in Neurodegeneration, INSERM UMR 1027, Faculté de Médecine de l'Université de Toulouse and Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
Farzin Khosrow-KhavarDepartment of Epidemiology, Biostatistics, and Occupational Health, Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Québec, Canada.
Agnès SommetService de Pharmacologie Médicale et Clinique, Centre de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CIC INSERM 1436, NeuroToul Centre of Excellence in Neurodegeneration, INSERM UMR 1027, Faculté de Médecine de l'Université de Toulouse and Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
Christel RenouxDepartment of Epidemiology, Biostatistics, and Occupational Health, Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Québec, Canada.
Jean-Louis MontastrucService de Pharmacologie Médicale et Clinique, Centre de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CIC INSERM 1436, NeuroToul Centre of Excellence in Neurodegeneration, INSERM UMR 1027, Faculté de Médecine de l'Université de Toulouse and Centre Hospitalier Universitaire de Toulouse, Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.ORCID 0000-0001-6341-6001 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Breast NeoplasmsParkinsonian DisordersAntineoplastic Agents, HormonalHumansTamoxifenAntineoplastic Agents, HormonalTamoxifen
What OpenQuestion holds
Textmetadata
Read underepoch 390